Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $5.17 Consensus Price Target from Analysts
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month […]
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month […]